Stock ABNX ABIONYX PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

Company ABIONYX Pharma

Equities

ABNX

FR0012616852

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:24 2024-04-26 am EDT 		5-day change 1st Jan Change
1.024 EUR +0.59% Intraday chart for ABIONYX Pharma -4.66% -20.50%
Mar. 14 Abionyx Pharma: to benefit from a 1ME grant from Bpifrance CF
Mar. 11 Abionyx: reduced net loss in 2023 CF

Business Summary

ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases.

At the end of 2022, the company boasted a portfolio of 3 products in clinical development.

Number of employees: 63

Sales per Business

EUR in Million2021Weight2022Weight Delta
Research
100.0 %
0 4.0 % 5 100.0 % +19,351.85%

Sales per region

EUR in Million2021Weight2022Weight Delta
France
100.0 %
1 100.0 % 5 100.0 % +678.07%

Managers

Managers TitleAgeSince
Cyrille Tupin CEO
 Chief Executive Officer 48 06-12-31
Emmanuel de Fougeroux DFI
 Director of Finance/CFO - 08-04-30
Renee Benghozi CTO
 Chief Tech/Sci/R&D Officer - 15-02-08
Constance Keyserling COO
 Chief Operating Officer - -
Laurent Guerci PRN
 Corporate Officer/Principal - 23-07-11

Members of the board

Members of the board TitleAgeSince
Olivier Martinez BRD
 Director/Board Member 54 -
Christian Chavy BRD
 Director/Board Member 75 15-02-05
Cyrille Tupin CEO
 Chief Executive Officer 48 06-12-31
Laura Coruzzi BRD
 Director/Board Member 71 15-05-26
Karen Noël BRD
 Director/Board Member 51 17-06-08
Emmanuel Huynh CHM
 Chairman 54 19-08-25

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 28,439,382 22,076,290 ( 77.63 %) 253,928 ( 0.8929 %) 77.63 %

Shareholders

NameEquities%Valuation
Cyrille Tupin
4.723 %
1,533,001 4.723 % 2 M €
Claresco Finance SA
0.0521 %
16,900 0.0521 % 17 887 €
UBS Asset Management France SA
0.0402 %
13,054 0.0402 % 13 816 €
Gestys SA
0.0308 %
10,000 0.0308 % 10 584 €
Rothschild & Co. Asset Management SCS
0.005053 %
1,640 0.005053 % 1 736 €
Allianz Global Investors GmbH (France)
0.002526 %
820 0.002526 % 868 €
Génération Vie SA
0.002234 %
725 0.002234 % 767 €

Company contact information

ABIONYX Pharma SA

33-43, avenue Georges Pompidou Bâtiment D2

31130, Balma

+33 5 62 24 97 06

http://www.abionyx.com
address ABIONYX Pharma(ABNX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sales per region

Ratings for ABIONYX Pharma

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.024 EUR
Average target price
10.5 EUR
Spread / Average Target
+925.39%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABIONYX PHARMA Stock ABIONYX Pharma
-20.50% 35.12M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.71B
ARGENX SE Stock argenx SE
+1.69% 22.02B
BIONTECH SE Stock BioNTech SE
-17.37% 20.9B
GENMAB A/S Stock Genmab A/S
-9.30% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ABNX Stock
  4. Company ABIONYX Pharma